Takeda's Millennium in-licenses Sunesis pan-Raf kinase inhibitor

Japanese drug major Takeda’s (TSE: 4502) US subsidiary Millennium has entered a license agreement for the development of USA-based Sunesis Pharmaceuticals' (Nasdaq: SNSS) oral, selective pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology.

Under the terms of the deal with Biogen Idec and Millennium, Sunesis has received a $4 million upfront payment from Millennium. Sunesis continues to be eligible to receive up to $60 million in pre-commercial milestone program payments and royalties on sales of future collaboration products. In addition, Sunesis has retained its future co-development and co-promotion rights.

Part of Biogen collaboration